TYVYT
Jul 27, 2026
PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?
Summary The PD-1 inhibitors market is led by Merck’s KEYTRUDA and Bristol Myers Squibb’s OPDIVO, which together still dominate global revenue and remain the standard-bearers in the category. Challenger PD-1 drugs such as Sanofi/Regeneron’s LIBTAYO, GSK’s JEMPERLI, and Incyte’s ZYNYZ have carved out positions...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
